Quick Takeaways
- Lara Sullivan filed SCHEDULE 13D/A for Pyxis Oncology, Inc. Common Stock, par value $0.001 per share (PYXS).
- Disclosed ownership: 11%.
- Date of event: 31 Mar 2025.
Lara Sullivan - 31 Mar 2025 SCHEDULE 13D/A Report for Pyxis Oncology, Inc. Common Stock, par value $0.001 per share (PYXS)
- Filing Manager
- Lara Sullivan
- Reporting Manager
- Lara Sullivan, M.D.
- Symbol
- PYXS
- Shares outstanding
- 67,288,198 shares
- Disclosed Ownership
- 7,543,007 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13D/A
- Filing time
- 02 Apr 2025, 21:25:47 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 23 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Lara Sullivan disclosed 11% ownership in Pyxis Oncology, Inc. Common Stock, par value $0.001 per share (PYXS) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 23 Dec 2024.
- Current filing was accepted on 02 Apr 2025, 21:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lara Sullivan, M.D. | 11% | 7,543,007 | 0 | 7,543,007 | /s/ Lara Sullivan | Lara Sullivan, President,Chief Executive Officer & Chief Medical Officer | 0001769457 |